MD1560Y - Metodă de tratament miniinvaziv al ascit-peritonitei spontane bacteriene la pacienţii cu ciroză hepatică decompensată - Google Patents
Metodă de tratament miniinvaziv al ascit-peritonitei spontane bacteriene la pacienţii cu ciroză hepatică decompensată Download PDFInfo
- Publication number
- MD1560Y MD1560Y MDS20210014A MDS20210014A MD1560Y MD 1560 Y MD1560 Y MD 1560Y MD S20210014 A MDS20210014 A MD S20210014A MD S20210014 A MDS20210014 A MD S20210014A MD 1560 Y MD1560 Y MD 1560Y
- Authority
- MD
- Moldova
- Prior art keywords
- peritonitis
- ascites
- spontaneous
- bacterial
- patients
- Prior art date
Links
- 206010003445 Ascites Diseases 0.000 title abstract 2
- 230000001580 bacterial effect Effects 0.000 title abstract 2
- 208000019425 cirrhosis of liver Diseases 0.000 title abstract 2
- 206010034674 peritonitis Diseases 0.000 title abstract 2
- 230000002269 spontaneous effect Effects 0.000 title abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 3
- 239000003242 anti bacterial agent Substances 0.000 abstract 2
- 238000013459 approach Methods 0.000 abstract 2
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical group [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 abstract 1
- 108010003272 Hyaluronate lyase Proteins 0.000 abstract 1
- 102000001974 Hyaluronidases Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 229940127218 antiplatelet drug Drugs 0.000 abstract 1
- 210000003567 ascitic fluid Anatomy 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 125000001271 cephalosporin group Chemical group 0.000 abstract 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 229940030606 diuretics Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960002773 hyaluronidase Drugs 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 abstract 1
- 238000002690 local anesthesia Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Invenţia se referă la medicină, în special la hepatologie şi poate fi utilizată pentru tratamentul miniinvaziv al ascit-peritonitei spontane bacteriene la pacienţii cu ciroză hepatică decompensată.Esenţa invenţiei constă în aceea că se efectuează terapia infuzională cu administrarea parenterală a antibioticelor, hepatoprotectorilor, plasmei, aminoacizilor, preparatelor reologice şi dezagregante, diureticelor, şi concomitent, sub anestezie locală, se efectuează accese puncţionale în regiunea fosei iliace stângi şi drepte şi sub rebordul costal drept, se evacuează lichidul ascitic, apoi prin aceleaşi accese, în fiecare regiune se introduce câte un amestec, care conţine 4...8 mg de dexametazonă dizolvată în 50...100 ml de soluţie de NaCl 0,9 %, hialuronidază 124...248 UI dizolvată în 100...200 ml de soluţie de NaCl 0,9 %, un antibiotic din grupa cefalosporinelor dizolvat în 50...100 ml de soluţie de NaCl 0,9 % şi un preparat antimicrobian din grupa nitroimidazolilor, în doză de 5...10 mg/ml şi în volum de 25...75 ml, zilnic, timp de 3...5 zile.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20210014A MD1560Z (ro) | 2021-02-25 | 2021-02-25 | Metodă de tratament miniinvaziv al ascit-peritonitei spontane bacteriene la pacienţii cu ciroză hepatică decompensată |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20210014A MD1560Z (ro) | 2021-02-25 | 2021-02-25 | Metodă de tratament miniinvaziv al ascit-peritonitei spontane bacteriene la pacienţii cu ciroză hepatică decompensată |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1560Y true MD1560Y (ro) | 2021-08-31 |
| MD1560Z MD1560Z (ro) | 2022-03-31 |
Family
ID=77635755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20210014A MD1560Z (ro) | 2021-02-25 | 2021-02-25 | Metodă de tratament miniinvaziv al ascit-peritonitei spontane bacteriene la pacienţii cu ciroză hepatică decompensată |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD1560Z (ro) |
-
2021
- 2021-02-25 MD MDS20210014A patent/MD1560Z/ro active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MD1560Z (ro) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ700182A (en) | Parenteral formulations for administering macrolide antibiotics | |
| EP0433765A1 (en) | The use of immunomodulants as synergistic agents of chemotherapeutics in tumor therapy | |
| Utz et al. | Amphotericin B toxicity: combined clinical staff conference at the National Institutes of Health | |
| MX2024006799A (es) | Metodos para el tratamiento de cáncer con prame positivo. | |
| EP3427781B1 (en) | Drug and device system for pressurized aerosol therapies into a mammalian hollow space | |
| MD1560Y (ro) | Metodă de tratament miniinvaziv al ascit-peritonitei spontane bacteriene la pacienţii cu ciroză hepatică decompensată | |
| CN105497010A (zh) | Egcg在制备对抗脓毒症细菌内毒素靶向药物中的应用 | |
| CN103596565B (zh) | 塞克硝唑在口腔感染治疗中的应用 | |
| US20190015606A1 (en) | Drug and Device System for Pressurized Aerosol Therapies into a Mammalian Hollow Space | |
| Bortolussi et al. | Treatment of Candida peritonitis by peritoneal lavage with amphotericin B | |
| US6878688B2 (en) | Method of treatment of malignant neoplasms and complex preparation having antineoplastic activity for use in such treatment | |
| BENNETT | Review of selected aspects of pharmacology | |
| CN113876777A (zh) | 尼达尼布治疗异常新生血管形成骨关节疾病的方法 | |
| RU94042656A (ru) | Способ лечения первичного рака печени и набор для лечения первичного рака печени | |
| Butler | Changes in renal function | |
| CN105769849B (zh) | 一种治疗卵巢癌的药物组合物 | |
| MD926Y (ro) | Metodă de tratament laparoscopic al ascit-peritonitei bacteriene spontane în ciroza hepatică decompensată | |
| UTZ | General side effects | |
| WO2019139228A8 (en) | Microorganism for delivering drug for treatment of gastrointestinal disease, which expresses and secretes cystatin, and pharmaceutical composition for preventing or treating gastrointestinal disease, which includes the same | |
| CN101014370A (zh) | 用于治疗由治疗剂诱导的神经毒性的银杏提取物 | |
| US6143742A (en) | Treatment for necrotizing infections | |
| MD927Y (ro) | Metodă de tratament al peritonitei spontane anaerobe în ciroza hepatică decompensată cu sindrom hepato-renal | |
| Bozzetti | Historical perspective on parenteral and enteral nutrition in oncology | |
| Okutomi et al. | Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice | |
| Chari et al. | Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 safety and efficacy update of the open-label, multicenter, phase 1b study (PAVO) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued |